

EXECUTIVE SUMMARY

January - June 2021



MAIN FIGURES €m


Revenue	EBITDA	EBIT
290.6 (+52%)	74.0 (+75%)	63.4 (+93%)
Net profit	Capex	Net cash
51.0 (+72%)	11.4 (56%)	56.1

2021 operating revenue guidance


Revenue to increase between 35%-40%

Doria® filed in Europe in Q1 2020 and in USA in Q4 2020

OPERATING REVENUE €m



SPECIALTY PHARMA BUSINESS €m



Heparin franchise* **€131.4m** (+26%) 45% of operating revenue

LMWH **€127.8m** (+27%)

Bemiparin sales **total €65.1m** (+26%)
Enoxaparin sales **€62.7m** (+27%)

Spain **€36.1m** (+8%)
International **€29.0m** (+58%)

- ✓ Directly Marketed in Germany, UK, Italy, Portugal, Spain and Poland
- ✓ Launched in 23 countries
- ✓ Approved in 26 countries in Europe and 27 in RoW


* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

TOLL MANUFACTURING BUSINESS €m

total **€94.5m** (+172%)



GROSS MARGIN €m



R&D EXPENSES


€11.9m (+10%)

2 Candidates Currently in Clinical Trials


PRODUCT	POTENTIAL INDICATION	CURRENT SITUATION			KEY MILESTONES
		Non-Clinical	I	II	
DORIA® Risperidone, monthly	Schizophrenia				In approval process in Europe and USA
Letrozole ISM® Long acting Letrozole	Breast cancer				Phase I started in November 2017
Risperidone, quarterly	Schizophrenia				

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

SG&A EXPENSES €m




EBITDA €m



EBITDA Pre-R&D¹ €m €85.9m (+62%)

EBITDA with flat R&D costs² €m €75.2m (+77%)

NET PROFIT €m



NEWS FLOW

SPECIALTY PHARMA

Sales of enoxaparin biosimilar

Additional new products to be launched

Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

TOLL MANUFACTURING

New contracts to be announced

Evolution of Moderna's vaccine manufacturing

ISM® TECHNOLOGY PLATFORM

Marketing authorisation for Risperidone ISM® in Europe and USA

Next steps of Letrozole ISM® to be discussed with regulatory authorities in H2 2021

(1) Calculated excluding R&D expenses in H1 2021 and H1 2020
 (2) Calculated recognizing the same amount of R&D expenses in H1 2021 as in H1 2020